Original Report

Health behaviors among testicular cancer survivors


 

Background With modern treatment, more than 95% of American men who are diagnosed with testicular cancer will be cured. Although there is growing evidence that these individuals may face heightened risk of cardiovascular disease after chemotherapy, there is a paucity of research to objectively classify health-promoting behaviors in this population and to identify the barriers to improving their health behaviors.

Objectives To identify health behavior patterns in a group of testicular cancer survivors (TCSs) and the barriers to more positive health behaviors and to examine the relationship between barriers, health behaviors, and quality of life (QOL).

Methods TCSs from the Pennsylvania State Cancer Registry who had been diagnosed during 1990-2005 completed a comprehensive survey about QOL, health behaviors, and barriers to optimal healthy behaviors. QOL, health behaviors, and the barriers were assessed for 189 respondents.

Results Smoking (25%), risky drinking (35%), elevated body-mass index (83%), poor diet (95% did not meet the guidelines for fruit and vegetable intake), and inadequate exercise (50%) were common. Barriers to achieving optimal health behaviors were categorized as either cancer-related or competing demands. Cancer-related barriers contributed to worse physical QOL, whereas competing demands related to worse mental-health–related QOL.

Limitations Our sample size was moderate and self-selected. In addition, we used self-reports rather than the more standardized observation or interview-based data collection.

Conclusion TCSs demonstrate behaviors that put them at increased risk for future cardiovascular disease and complications. Interventions aimed at reducing tobacco and risky alcohol use and improving dietary and physical activity levels are needed.

Funding/sponsorship NCI grant number 1R03CA124217; the Livestrong Foundation. Disclosures The authors have no disclosures.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Positive surgical margins do not independently predict prostate cancer mortality
MDedge Hematology and Oncology
The push for smaller, smarter cancer trials
MDedge Hematology and Oncology
No benefit from androgen deprivation therapy in localized prostate cancer
MDedge Hematology and Oncology
I-125 brachytherapy for prostate cancer linked to small increase in bladder cancer risk
MDedge Hematology and Oncology
Prostate cancer screening fell in wake of trial results, task force recommendations
MDedge Hematology and Oncology
Low UTI rates after foregoing prophylactic antibiotics for cystoscopy
MDedge Hematology and Oncology
Biomarkers in urine outperformed cytology and cytoscopy
MDedge Hematology and Oncology
Prophylactic tadalafil ineffective after prostate cancer radiotherapy
MDedge Hematology and Oncology
Women had worse survival after radical cystectomy
MDedge Hematology and Oncology
First reported case of tumor hypoglycemia from recurrent renal cell carcinoma
MDedge Hematology and Oncology